Breaking News Instant updates and real-time market news.

KURA

Kura Oncology

$18.85

(0.00%)

, ACOR

Acorda Therapeutics

$25.60

0.65 (2.61%)

04:55
02/15/18
02/15
04:55
02/15/18
04:55

Leerink to hold a conference

7th Annual Global Healthcare Conference is being held in New York on February 14-15.

KURA

Kura Oncology

$18.85

(0.00%)

ACOR

Acorda Therapeutics

$25.60

0.65 (2.61%)

VCEL

Vericel

$7.30

-0.05 (-0.68%)

ITCI

Intra-Cellular

$19.19

1.46 (8.23%)

JNJ

Johnson & Johnson

$129.67

-0.29 (-0.22%)

CRL

Charles River

$110.31

2.65 (2.46%)

TOCA

Tocagen

$12.24

0.33 (2.77%)

ZFGN

Zafgen

$8.91

0.72 (8.79%)

AZN

AstraZeneca

$33.49

0.38 (1.15%)

IMGN

ImmunoGen

$10.15

0.35 (3.57%)

FATE

Fate Therapeutics

$7.99

0.14 (1.78%)

TECH

Bio-Techne

$141.06

4.06 (2.96%)

RGEN

Repligen

$32.99

0.67 (2.07%)

QURE

uniQure

$24.42

2.31 (10.45%)

CNMD

Conmed

$60.10

0.48 (0.81%)

DEPO

DEPO

BMY

Bristol-Myers

$65.35

1.48 (2.32%)

BSX

Boston Scientific

$26.81

0.7 (2.68%)

CAH

Cardinal Health

$67.34

1.65 (2.51%)

SNY

Sanofi

$39.86

0.46 (1.17%)

AGN

Allergan

$166.63

7.91 (4.98%)

AMRN

Amarin

$3.63

0.1 (2.83%)

MNTA

Momenta

$16.25

0.25 (1.56%)

RGNX

Regenxbio

$26.80

0.2 (0.75%)

  • 15

    Feb

  • 15

    Feb

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 21

    Feb

  • 21

    Feb

  • 26

    Feb

  • 01

    Mar

  • 05

    Mar

  • 05

    Mar

  • 08

    Mar

  • 12

    Mar

  • 14

    Mar

  • 25

    Mar

  • 04

    Apr

  • 23

    Apr

  • 02

    May

KURA Kura Oncology
$18.85

(0.00%)

12/20/17
WEDB
12/20/17
INITIATION
Target $19
WEDB
Outperform
Kura Oncology initiated with an Outperform at Wedbush
Wedbush initiated Kura Oncology with an Outperform and $19 price target.
08/08/17
SBSH
08/08/17
NO CHANGE
Target $13
SBSH
Buy
Kura Oncology Phase 2 trial update 'encouraging,' says Citi
Citi analyst Joel Beatty views Kura Oncology's Phase 2 HRAS mutant SCCHN trial update as "encouraging." Though the number of patients is still small, the 60% partial response rate is higher than the 13%-16% rate seen historically with approved agents in the squamous cell carcinomas of the head and neck setting, Beatty tells investors in a research note. He raised his price target for Kura shares to $13 from $12 and keeps a Buy rating on the name.
09/07/17
COWN
09/07/17
INITIATION
COWN
Outperform
Kura Oncology initiated with an Outperform at Cowen
Cowen analyst Chris Shibutani initiated Kura Oncology with an Outperform saying its uniquely positioned to generate significant value from its precision based approach to developing its lead compound, tipifarnib. The analyst said recent clinical data increases confidence in tipifarnib's opportunity in HRAS-mutan SCCHN, with additional opportunity in PTCL. Shibutani sees a commercial peak sales of $600M+ for these orphan oncology indications.
11/09/17
SBSH
11/09/17
NO CHANGE
Target $19
SBSH
Buy
Kura Oncology price target raised to $19 from $15 at Citi
Citi analyst Joel Beatty raised his price target for Kura Oncology to $19 ahead of next week's investor meeting and keeps a Buy rating on the shares. The analyst believes the data to date for Tipifarnib in HRAS-mutant head and neck squamous cell carcinoma suggests it could be superior to the 13%-16% response rate typically seen with the standard of care.
ACOR Acorda Therapeutics
$25.60

0.65 (2.61%)

01/31/18
JANY
01/31/18
NO CHANGE
JANY
Neutral
Competitor Phase 3 'takes some shine off' Acorda Therapeutics, says Janney Capital
Janney Capital analyst Ken Trbovich notes that Sunovion Pharmaceuticals, a wholly owned U.S.-based subsidiary of Sumitomo Dainippon Pharma, reported positive top-line results from its Phase 3 trial of APL-130277 for treating OFF-rescue in Parkinson's Disease patients. While the respective Phase 3 studies were not head-to-head, it would appear APL-130277 may be the more potent OFF rescue treatment, with the trade-off being higher rates unpleasant side effects such as nausea and dizziness, the analyst notes. Trbovich believes this could take some of the luster off perceived M&A value of Acorda Therapeutics, but it is unlikely to eliminate interest. He reiterates a Neutral rating on Acorda Therapeutics' shares.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.
11/28/17
PIPR
11/28/17
INITIATION
Target $22
PIPR
Neutral
Acorda Therapeutics assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Charles Duncan assumed coverage of Acorda Therapeutics with a Neutral rating and $22 price target. The analyst believes Inbrija could be a best-in-class acute treatment with $800M in peak U.S. sales. He's looking for clinical and regulatory progress "which re-establishes conviction in Acorda's execution."
11/21/17
JANY
11/21/17
NO CHANGE
Target $17
JANY
Neutral
Acorda could be worth $17-$27 in takeover, says Janney Capital
After Acorda Therapeutics announced that it is discontinuing development of tozadenant, an investigational treatment for Parkinson's disease, Janney Capital analyst Ken Trbovich said he believes a sale process appears necessary to protect shareholders from downside that he sees if Acorda remains independent. While the stock may only be worth $10-$11 if Acorda stays independent, it could be worth $17-$27 in a takeout scenario, estimated Trbovich, who maintains a Neutral rating and $17 fair value estimate on Acorda shares.
VCEL Vericel
$7.30

-0.05 (-0.68%)

01/02/18
PIPR
01/02/18
NO CHANGE
Target $9
PIPR
Overweight
Vericel price target raised to $9 from $7 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Vericel to $9 after the company received $5.1M from Chinese partner ICT. The analyst expects "healthy" MACI sales growth to drive value and reiterates an Overweight rating on Vericel.
10/05/17
10/05/17
NO CHANGE

Piper keeps Vericel at Overweight, says ixmyelocel-T not in model
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $7 price target on Vericel after the company announced it met with FDA and will be required to conduct an additional study to support a BLA filling for ixmyelocel-T in ischemic dilated cardiomyopathy. Tenthoff noted that Piper did not currently value ixmyelocel-T, and that Vericel did not intend to conduct any additional studies without a partner.
06/20/17
BTIG
06/20/17
INITIATION
BTIG
Buy
Vericel initiated with a Buy at BTIG
BTIG analyst Ryan Zimmerman started Vericel with a Buy rating and $6 price target, citing its first mover advantage in advanced cartilage repair and a simplified technique for surgeons.
ITCI Intra-Cellular
$19.19

1.46 (8.23%)

12/15/17
ADAM
12/15/17
INITIATION
Target $31
ADAM
Buy
Intra-Cellular initiated with a Buy at Canaccord
Canaccord initiated Intra-Cellular with a Buy and $31 price target.
02/08/18
RBCM
02/08/18
INITIATION
Target $33
RBCM
Outperform
Intra-Cellular initiated at Outperform at RBC Capital
RBC Capital analyst Brian Abrahams initiated Intra-Cellular with an Outperform rating and a price target of $33. The analyst believes that the company's "valuation underappreciates the likelihood of approval of lead drug ITCI-007 in schizophrenia and the market opportunity of '007 across various psychiatric indications". Abrahams recommends that investors buy into the upcoming regulatory interactions and potential launch.
11/09/17
RHCO
11/09/17
UPGRADE
Target $22
RHCO
Buy
Intra-Cellular upgraded to Buy at SunTrust on valuation
As previously reported, SunTrust analyst Edward Nash upgraded Intra-Cellular to Buy from Hold and kept his $22 price target. Nash says the outlook for FY18 has been conservative, adding that the recent pull-back in shares created a buying opportunity. The analyst is positive on the company's plans to file NDA for lumateperone in schizophrenia by mid-2018 as well as its three ongoing Phase III trials for bi-polar depression expected to fully enroll in FY18.
11/08/17
RHCO
11/08/17
UPGRADE
RHCO
Buy
Intra-Cellular upgraded to Buy from Hold at SunTrust
JNJ Johnson & Johnson
$129.67

-0.29 (-0.22%)

02/06/18
WELS
02/06/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson talc litigation concerns appear overblown, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen says Johnson & Johnson shares were down partly due to concerns about ongoing litigation over allegations that its talcum power products are unsafe for use because they contain asbestos which can cause mesothelioma. Based on prior high-profile product liability cases in the drug and device sectors, the analyst believes any potential settlement would be manageable for Johnson & Johnson. He reiterates an Outperform rating and $160 price target on the shares.
01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/18/18
MSCO
01/18/18
NO CHANGE
Target $157
MSCO
Equal Weight
Zytiga ruling a headwind, but doesn't change J&J thesis, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Johnson & Johnson suffered an adverse Zytiga IPR ruling, which he calls an incremental headwind. However, he added that a possible earlier generic Zytiga entry is irrelevant to his net present value for J&J shares and doesn't change his view that its Pharma growth accelerates in 2018. Lewis keeps an Equal Weight rating and $157 price target on J&J shares.
CRL Charles River
$110.31

2.65 (2.46%)

01/22/18
RHCO
01/22/18
DOWNGRADE
Target $111
RHCO
Hold
Charles River downgraded to Hold at SunTrust on valuation
As reported earlier, SunTrust analyst Sandy Draper downgraded Charles River to Hold from Buy and lowered his price target to $111 from $113 as part of his broader "CRO Universe 2018 preview" research note. Draper says that while the momentum of a strong CRO industry carries into 2018, the PE valuations are now ahead of the 2- and 5-year averages, and the year should be "largely contingent on underlying earnings generation rather than further multiple expansion". For Charles River, Draper says the valuation "no longer excites us", adding there are downside risks from "weaker demand from large pharma due to less outsourcing or consolidation" as well as cost inflation margin pressure.
01/22/18
RHCO
01/22/18
DOWNGRADE
RHCO
Hold
Charles River downgraded to Hold from Buy at SunTrust
02/14/18
RHCO
02/14/18
UPGRADE
Target $125
RHCO
Buy
Charles River upgraded to Buy at SunTrust on MPI acquisition
As reported earlier, SunTrust analyst Sandy Draper upgraded Charles River to Buy from Hold and raised his price target to $125 from $111. Draper says the January downgrade contained a caveat of a " large and materially accretive M&A deal", reversing that call following the company's announcement to acquire MPI. The analyst believes that the EPS accretion should push earnings growth to 8-9% this year and 15% next year.
02/14/18
RHCO
02/14/18
UPGRADE
RHCO
Buy
Charles River upgraded to Buy from Hold at SunTrust
TOCA Tocagen
$12.24

0.33 (2.77%)

05/09/17
EVER
05/09/17
INITIATION
Target $28
EVER
Outperform
Tocagen initiated with an Outperform at Evercore ISI
Evercore ISI analyst Jonathan Miller initiated Tocagen with an Outperform and a $28 price target
05/08/17
05/08/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Yext (YEXT) initiated with an Outperform at RBC Capital, with an Overweight at Piper Jaffray, with an Equal Weight at Morgan Stanley and with a Neutral at JPMorgan. 2. Netshoes (NETS) initiated with an Overweight at JPMorgan and with a Buy at Jefferies. 3. Tocagen (TOCA) initiated with a Buy at Stifel and with a Market Perform at Leerink. 4. Warrior Met Coal (HCC) initiated with an Outperform at BMO Capital, with an Overweight at Morgan Stanley, with an Outperform at Credit Suisse and with a Neutral at Citi. 5. Cadence Bancorporation (CADE) initiated with an Outperform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/08/17
LEER
05/08/17
INITIATION
Target $19
LEER
Market Perform
Tocagen initiated with a Market Perform at Leerink
Leerink analyst Michael Schmidt started Tocagen with a Market Perform rating and $19 price target.
05/08/17
STFL
05/08/17
INITIATION
STFL
Buy
Tocagen initiated at Stifel
As noted earlier, Stifel started coverage of Toca with a $24 price target and a Buy rating. Analyst Thomas Shrader says that data on the company's combination cancer treatment, TOCA-511 + TOCA-FC, in high grade glioma is "intriguing." "Most treated patients live longer than historical expectations and about 25% of patients experience profound responses lasting years and possibly representing a cure," he wrote. The analyst adds that "solid" data indicates that other types of solid tumors could be mitigated using the drug combination.
ZFGN Zafgen
$8.91

0.72 (8.79%)

04/20/17
ROTH
04/20/17
INITIATION
Target $9
ROTH
Buy
Zafgen initiated with a Buy at Roth Capital
Roth Capital analyst Sa'ar Yaniv started Zafgen with a Buy rating and $9 price target as he expects a number of events over the coming 12 months to drive investor interest.
AZN AstraZeneca
$33.49

0.38 (1.15%)

12/29/17
12/29/17
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. AstraZeneca (AZN) upgraded to Overweight from Neutral at JPMorgan with analyst James Gordon saying the company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium. 2. PriceSmart (PSMT) upgraded to Outperform from Market Perform at IFS Securities. 3. Novo Nordisk (NVO) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he expects "strong" oral semaglutide Phase III newsflow in 2018. 4. Syntel (SYNT) downgraded to Underperform from Market Perform at Wells Fargo with analyst Ed Caso saying he sees the company's "weak" positioning for the ongoing shift in information technology demand from "legacy" low-cost offshore-centric software services to more onshore-necessary "digital" solutions as dragging down its growth and margins. 5. RioCan REIT downgraded to Sector Perform from Outperform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/29/17
JPMS
12/29/17
UPGRADE
JPMS
Overweight
AstraZeneca upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded AstraZeneca to Overweight and raised his price target for the shares to 55 pounds from 48 pounds. The company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium, Gordon tells investors in a research note. He believes downside risk around the Mystic trial failure and "overly high base business expectations" have now lessened with consensus earnings forecasts declining 15%. The analyst expects AstraZeneca to return to sales growth in 2018, even without further immuno-oncology trial success. Astra has 10 Phase III readouts, with fairly low expectations across the board, Gordon argues.
01/02/18
ADAM
01/02/18
NO CHANGE
Target $77
ADAM
Buy
ANI Pharmaceuticals best positioned in emerging generics space, says Canaccord
Canaccord analyst Dewey Steadman said ANI Pharmaceuticals (ANIP) is one of the best positioned names in the emerging generics space. He noted the company has a basket of additional branded tail assets from its AstraZeneca (AZN) acquisitions, additional cash on hand and credit facilities for future transactions, and a solid core business. Steadman reiterated his Buy rating and raised his price target to $77 from $75 on ANI Pharmaceuticals shares.
01/22/18
WELS
01/22/18
NO CHANGE
WELS
Underperform
Teva can't afford more pipeline setbacks, says Wells Fargo
After Teva (TEVA) reported that its Phase 3 registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint, Wells Fargo analyst David Maris said he believes this puts Teva at a disadvantage versus peers AstraZeneca (AZN) and GlaxoSmithKline (GSK) at a time when Teva cannot afford more pipeline setbacks. Subcutaneous reslizumab was not a major focus, but the news is still "another disappointment," said Maris, who keeps an Underperform rating on Teva shares.
IMGN ImmunoGen
$10.15

0.35 (3.57%)

01/31/18
01/31/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lumentum (LITE) was initiated with a Buy at UBS while Oclaro (OCLR) was initiated with a Sell. 2. ImmunoGen (IMGN) initiated with a Buy at H.C. Wainwright. 3. Salesforce (CRM) and Workday (WDAY) were initiated with a Buy at Cleveland Research. 4. Cooper Tire (CTB) was initiated with a Buy at Longbow, while Goodyear Tire (GT) was initiated with a Neutral. 5. Acacia Communications (ACIA) initiated with a Buy at UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/18
HCWC
01/31/18
INITIATION
Target $18
HCWC
Buy
ImmunoGen initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started ImmunoGen with a Buy rating and $18 price target. The analyst believes ADC's, a multi-component system involving a targeting antibody linked to cytotoxic agents, have a "significant and hitherto underappreciated role to play in the war against cancer." He believes ImmunoGen has a differentiated ADC platform.
02/08/18
RBCM
02/08/18
INITIATION
Target $12
RBCM
Outperform
ImmunoGen assumed with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay assumed coverage of ImmunoGen with an Outperform rating and a price target of $9. MacKay notes "mirvetuximab's market opportunity in 2L+ platinum-resistant/refractory folate receptor alpha positive ovarian cancer", modeling potential $850M in peak risk-unadjusted sales. MacKay also points to the positive impact of U.S. tax changes and believes 2018 could be a "transformational year" with a scheduled futility analysis planned ahead of top-line data in the first half of 2019.
12/18/17
LEER
12/18/17
NO CHANGE
LEER
Puma Biotechnology, Clovis top picks in biotech for 2018 at Leerink
Leerink analyst Michael Schmidt expects oncology to remain an attractive area within Biotech in 2018. Key product launches, a rich set of pivotal trial results, and pending regulatory decisions among stocks he covers make 2018 a catalyst-rich year, particularly in the first half of 2018, the analyst contends. Puma Biotechnology (PBYI) and Clovis (CLVS) are Schmidt's top-picks with Incyte (INCY) as a close third. Additionally, he sees ImmunoGen (IMGN) and Karyopharm (KPTI) as attractive emerging small-caps for 2018.
FATE Fate Therapeutics
$7.99

0.14 (1.78%)

10/12/17
HCWC
10/12/17
INITIATION
Target $7
HCWC
Buy
Fate Therapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White assumed coverage of Fate Therapeutics with a Buy rating and $7 price target. The analyst projects revenues of $329M and $68M for ProTmune and NK-100, respectively, in 2026.
12/18/17
PIPR
12/18/17
INITIATION
Target $10
PIPR
Overweight
Fate Therapeutics initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff started Fate Therapeutics with an Overweight rating and $10 price target. The company is developing a pipeline of induced pluripotent stem cell-derived cell therapies that could revolutionize cancer immunotherapy, the analyst contends.
09/08/17
09/08/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DowDuPont (DWDP) initiated with a Top Pick at RBC Capital. 2. Electronic Arts (EA) was initiated with a Conviction Buy while Activision Blizzard (ATVI) was initiated with a Neutral at Goldman Sachs. 3. AB InBev (BUD) initiated with a Buy at Argus. 4. LivaNova (LIVN) initiated with a Buy at Jefferies. 5. Fate Therapeutics (FATE) resumed with an Outperform at Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/18
PIPR
01/04/18
NO CHANGE
Target $10
PIPR
Fate Therapeutics named a top pick for 2018 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff names Fate Therapeutics a top pick for 2018 with an Overweight rating and $10 price target. The analyst is positive on the FATE-NK100 data and investigational new drug filings on the first-ever iPSC-derived cell therapies.
TECH Bio-Techne
$141.06

4.06 (2.96%)

02/07/18
CHLM
02/07/18
NO CHANGE
Target $160
CHLM
Buy
Bio-Techne price target raised to $160 from $140 at Craig-Hallum
Craig-Hallum analyst Matt Hewitt raised his price target for Bio-Techne to $160 from $140 saying the "impressive" Q2 beat shows off "strong" biotech core and is "packed full of protein platforms." The analyst reiterates a Buy rating on the shares.
10/24/17
SBSH
10/24/17
NO CHANGE
Target $145
SBSH
Buy
Bio-Techne price target raised to $145 from $125 at Citi
Citi analyst Daniel Arias raised his price target for Bio-Techne to $145 saying he sees room for more upside even with the shares up 20% year-to-date. The analyst views the company as "one of the better set-up stories" in the tools space and believes the shares can "grind higher" into fiscal 2018. He keeps a Buy rating on the name.
12/05/17
LEER
12/05/17
NO CHANGE
LEER
Outperform
ACD to remain leading growth engine for Bio-Techne, says Leerink
Leerink analyst Puneet Souda reiterates an Outperform on Bio-Techne with his view that its consumables-heavy portfolio including its Advanced Cell Diagnostics business should continue to deliver on above-industry growth and gross margins in his Life Science Tools coverage universe.
10/31/17
DBAB
10/31/17
NO CHANGE
Target $145
DBAB
Buy
Bio-Techne price target raised to $145 from $140 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Bio-Techne to $145 saying Q1 marked the second consecutive quarter of high-single digit organic growth. The company's accelerating revenue growth profile could sustain its premium valuation, Leonard tells investors in a post-earnings research note. He keeps a Buy rating on Bio-Techne.
RGEN Repligen
$32.99

0.67 (2.07%)

11/13/17
KING
11/13/17
INITIATION
Target $41
KING
Buy
Repligen initiated with a Buy at CL King
CL King initiated Repligen with a Buy and $41 price target telling investors its premium valuation is justified given potential strong double-digit growth and operating margin expansion.
12/05/17
12/05/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Repligen (RGEN) initiated with an Overweight at JPMorgan. 2. Delphi Technologies (DLPH) was initiated with an Overweight at Morgan Stanley and a Buy at Goldman Sachs. 3. Aptiv (APTV) initiated with an Underweight at Morgan Stanley. 4. Michael Kors (KORS) reinstated with a Buy at Goldman Sachs. 5. Bandwidth (BAND) was initiated with an Outperform at Baird and JMP Securities, an Overweight at KeyBanc and Morgan Stanley, as well as a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/05/17
JPMS
12/05/17
INITIATION
Target $42
JPMS
Overweight
Repligen initiated with an Overweight at JPMorgan
JPMorgan analyst Tycho Peterson started Repligen with an Overweight rating and $42 price target. The analyst views the company as the "best pure-play bioprocessing supplier."
12/08/17
SBSH
12/08/17
INITIATION
Target $45
SBSH
Buy
Repligen initiated with a Buy at Citi
Citi analyst Daniel Arias started Repligen with a Buy rating and $45 price target. Repligen is well positioned as a pure-play within one of the most attractive portions of the life sciences market, Arias tells investors in a research note. The analyst believes the recent pullback provides a good buying opportunity.
QURE uniQure
$24.42

2.31 (10.45%)

01/03/18
JANY
01/03/18
INITIATION
Target $25
JANY
Buy
uniQure initiated with a Buy at Janney Capital
Janney analyst Yun Zhong initiated uniQure with a Buy rating and $25 price target.
11/27/17
OPCO
11/27/17
NO CHANGE
OPCO
Oppenheimer dropping coverage of uniQure
Oppenheimer is dropping coverage of uniQure due to a reallocation of analyst resources.
02/05/18
HCWC
02/05/18
NO CHANGE
Target $28
HCWC
Buy
uniQure should be bought at current levels, says H.C. Wainwright
In a research note on uniQure titled "Seeking Alpha in a High Beta Environment," H.C. Wainwright analyst Debjit Chattopadhyay says "enough with the discount already!" uniQure, along with other gene therapy and gene editing peers, could emerge as a "compelling" stock for the long run as healthcare evolves to a differentiated and value-based commercial market, Chattopadhyay tells investors in a research note. The analyst believes the company's positioning to be the first to commercialize a once-and-done solution for Hemophilia B gives it an advantage. Chattopadhyay recommends investors initiate or add to positions in uniQure.
12/01/17
HCWC
12/01/17
INITIATION
Target $28
HCWC
Buy
uniQure initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started uniQure with a Buy rating and $28 price target. The company may be able to deliver a curative option for patients with Hemophilia B well ahead of the competition, which is likely to be disruptive to the $2B global commercial opportunity, the analyst contends.
CNMD Conmed
$60.10

0.48 (0.81%)

04/27/17
LEER
04/27/17
NO CHANGE
Target $52
LEER
Market Perform
CONMED price target raised to $52 from $45 at Leerink
Leerink analyst Richard Newitter raised his price target for CONMED to $52 from $45 after the company delivered a "good Q1" with revenue/EPS ahead of expectations. The analyst reiterates a Market Perform rating on the shares.
02/01/18
NEED
02/01/18
NO CHANGE
Target $71
NEED
Buy
CONMED price target raised to $71 from $58 at Needham
Needham analyst Mike Matson raised his price target on CONMED to $71 and kept his Buy rating after Q4 earnings beat. The analyst says the company has "finally turned around its US Orthopedics business which was the one remaining drag on its growth". Matson also cites the management's forecast of sustaining mid-single digit revenue growth and double-digit EPS growth, which he adds may prove to be conservative.
04/27/17
NEED
04/27/17
NO CHANGE
Target $54
NEED
Buy
CONMED price target raised to $54 from $48 at Needham
Needham analyst Mike Matson raised his price target for CONMED to $54 from $48 after the company's Q1 revenue and EPS beat consensus and management maintained its 2017 guidance. The analyst is encouraged by the improvement in revenue growth and reiterates a Buy rating, though he needs to see it sustained for a few more quarters before he is comfortable declaring the CONMED turnaround a success.
02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
DEPO DEPO

12/05/17
12/05/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McDonald's (MCD) upgraded to Buy from Hold at Jefferies with analyst Andy Barish saying McDonald's is well positioned in the current environment to continue to outperform. 2. Snap (SNAP) upgraded to Overweight from Equal Weight at Barclays with analyst Ross Sandler sayign with the company's pricing transition in the later stages, Snap may start hitting or exceeding consensus revenue estimates and accelerating growth in 2018. 3. Depomed (DEPO) upgraded to Buy from Neutral at Mizuhom with analyst Irina Koffler citing the company's agreement to license rights to commercialize the Nucynta franchise to Collegium (COLL). 4. United Technologies (UTX) upgraded to Overweight from Neutral at Atlantic Equities. 5. Earthstone Energy (ESTE) upgraded to Buy from Neutral at Seaport Global with analyst Mike Kelly citing the October 18 capital raise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/05/17
MZHO
12/05/17
UPGRADE
MZHO
Buy
Depomed upgraded to Buy from Neutral at Mizuho
12/05/17
12/05/17
UPGRADE
Target $9

Buy
Depomed upgraded to Buy after opiod exit deal at Mizuho
As previously reported, Mizuho analyst Irina Koffler upgraded Depomed (DEPO) to Buy from Neutral after the company agreed to license rights to commercialize the Nucynta franchise to Collegium (COLL). With the deal, Depomed exits the opioid space and significantly lowers its operating expenses, said Koffler, who raised her price target on Depomed shares to $9 from $6.
12/05/17
NEED
12/05/17
NO CHANGE
Target $28
NEED
Buy
Collegium Pharmaceutical price target raised to $28 from $25 at Needham
Needham analyst Serge Belanger raised his price target on Collegium Pharmaceutical (COLL) after its agreement with Depomed (DEPO) to license U.S. commercial rights of Nucynta and Nucynta ER. Belanger says the transaction allows the company to "leverage its commercial infrastructure given the significant overlap with Xtampza's target audience of pain specialists", estimating that it adds about $3-$5 to the company valuation. The analyst keeps his Buy rating on Collegium Pharmaceutical, noting that the deal moves up the timelines for profitability.
BMY Bristol-Myers
$65.35

1.48 (2.32%)

02/06/18
LEER
02/06/18
NO CHANGE
Target $76
LEER
Outperform
Bristol-Myers price target raised to $76 from $71 at Leerink
Leerink analyst Seamus Fernandez raised his price target for Bristol-Myers to $76 from $71 and increased Opdivo and Yervoy estimates following positive CM-227 PFS Topline. The analyst reiterates an Outperform rating on the shares.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $88
JEFF
Buy
Bristol-Myers makes sense as potential Nektar acquirer, says Jefferies
Jefferies analyst David Steinberg believes Bloomberg's report that Nektar Therapeutics (NKTR) is exploring strategic options is not surprising. For many years Nektar's most important assets were out licensed, but that is no longer the case, Steinberg tells investors in a research note. The company's current partner Bristol-Myers Squibb (BMY) would make sense to be on the short list of potential acquirer, the analyst adds. Steinberg keeps a Buy rating on Nektar with an $88 price target.
02/14/18
MZHO
02/14/18
NO CHANGE
Target $89
MZHO
Buy
Nektar deal with Bristol-Myers could eventually lead to takeover, says Mizuho
After Nektar (NKTR) announced a new immune-oncology collaboration agreement with Bristol-Myers Squibb (BMY), Mizuho analyst Difei Yang said she believes the deal values Nektar at approximately $9B-$10B and may lead to an eventual takeout. She maintains her Buy rating and $89 price target on Nektar shares.
02/14/18
JEFF
02/14/18
NO CHANGE
Target $88
JEFF
Buy
Nektar takeover not off table with Bristol deal, says Jefferies
Jefferies analyst David Steinberg finds it important that Nektar Therapeutics (NKTR) retains ownership of NKTR-214 following its collaboration with Bristol-Myers (BMY) and that it can continue to collaborate with other companies. Further, the potential to be acquired is not off the table, Steinberg tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $88 price target.
02/15/18
MSCO
02/15/18
UPGRADE
MSCO
Overweight
Bristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
02/15/18
SBSH
02/15/18
NO CHANGE
Target $62
SBSH
Neutral
Alkermes catalysts are the major focus this year, says Citi
Citi analyst Liav Abraham says that while Alkermes' (ALKS) fiscal 2018 revenue outlook came in below expectations, catalysts are the "major force this year." The analyst expects data from two of the company's pivotal programs and clarity around the regulatory pathway for ALKS 5461. Further, the strategic value of ALKS 4230 "can also not be discounted," following the collaboration between Bristol-Myers (BMY) and Nektar Therapeutics (NKTR), Abraham tells investors in a post-earnings research note. ALKS 4230, an IL-2 inhibitor, gives Alkermes optionality as it is not an "obvious" fit into the company's psychiatry-oriented portfolio, the analyst contends. She keeps a Neutral rating on Alkermes with a $62 price target.
BSX Boston Scientific
$26.81

0.7 (2.68%)

01/09/18
LEER
01/09/18
NO CHANGE
LEER
Outperform
Boston Scientific should outperform on 'strong beat,' says Leerink
Leerink analyst Danielle Antalffy notes that Boston Scientific preannounced better than expected Q4 results. The analyst sees this quarterly performance as particularly encouraging, given the fact that Boston Scientific delivered outperformance across all business segments despite facing a tough comp. Antalffy expects the stock to outperform on this strong beat, and continues to believe Boston Scientific represents "one of the most attractive" top-line growth stories in large-cap MedTech. She reiterates an Outperform rating on the shares.
01/05/18
RBCM
01/05/18
UPGRADE
Target $31
RBCM
Top Pick
Boston Scientific upgraded to Top Pick at RBC Capital
As reported earlier, RBC Capital analyst Glenn Novarro upgraded Boston Scientific to Top Pick from Outperform, keeping his $31 price target. Novarro says the Q4 earnings expected out on February 1st will be a positive catalyst in addressing concerns around 2018 outlook in late November when the company announced another delay in its LOTUS Edge system.
01/05/18
RBCM
01/05/18
UPGRADE
RBCM
Top Pick
Boston Scientific upgraded to Top Pick from Outperform at RBC Capital
CAH Cardinal Health
$67.34

1.65 (2.51%)

12/04/17
DBAB
12/04/17
INITIATION
Target $64
DBAB
Hold
Cardinal Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Glen Santangelo started Cardinal Health with a Hold rating and $64 price target. The analyst believes uncertainty around drug pricing and the potential for integration risk with Cordis and the Patient Recovery acquisitions warrant a "more prudent approach" to the shares.
12/04/17
LEER
12/04/17
NO CHANGE
LEER
Amazon entry into healthcare markets focused on medical supplies, says Leerink
Leerink analyst David Larsen says that his recent research around Amazon's (AMZN) licensing activity has shown that the company's entry into healthcare markets is, at least for now, focused on medical supplies and devices rather than pharmaceuticals. The analyst believes Owens & Minor (OMI), Cardinal Health (CAH) and Henry Schein (HSIC) are most exposed but that it will take several years for Amazon Business to scale up manufacturer supply relationships to take significant share. Although the top and bottom line impact may be small over the next year or two, Larsen remains cautious on the group as multiples continue to reflect the Amazon threat as well as pricing and volume headwinds.
02/14/18
JEFF
02/14/18
NO CHANGE
JEFF
Amazon focusing on bolstering medical device distribution, says Jefferies
Yesterday's Wall Street Journal report and a recent scan of job postings still point to Amazon.com's (AMZN) focus on bolstering its medical device/supplies distribution capabilities, specifically targeting hospitals, Jefferies analyst Brian Tanquilut. These postings support a negative thesis for Cardinal Health (CAH), Owens & Minor (OMI) and Premier's (PINC) medical supplies businesses, the analyst adds. Further, he sees the news as an incremental positive for AmerisourceBergen (ABC), McKesson (MCK), CVS Health (CVS) and Walgreens Boots Alliance (WBA) since it further supports the view that Amazon isn't looking to enter the prescription business near-term.
01/04/18
EVER
01/04/18
INITIATION
Target $67
EVER
In Line
Cardinal Health initiated with an In Line at Evercore ISI
Evercore ISI started Cardinal Health with an In Line rating and $67 price target.
SNY Sanofi
$39.86

0.46 (1.17%)

02/08/18
BERN
02/08/18
NO CHANGE
Target $45
BERN
Market Perform
Sanofi price target lowered to $45 from $50 at Bernstein
Bernstein analyst Tim Anderson lowered his price target for Sanofi to $45 from $50 following a "weak" quarter. The analyst reiterates a Market Perform rating on the shares.
01/24/18
FBCO
01/24/18
NO CHANGE
Target $105
FBCO
Neutral
Bioverativ price target raised to $105 from $65 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for Bioverativ (BIVV) to $105 from $65 ahead of likely closing of the Sanofi (SNY) deal. The analyst reiterates a Neutral rating on Bioverativ's shares.
01/23/18
LEHM
01/23/18
DOWNGRADE
LEHM
Underweight
Sanofi downgraded to Underweight from Equal Weight at Barclays
01/24/18
ARGS
01/24/18
DOWNGRADE
ARGS
Hold
Bioverativ downgraded to Hold from Buy at Argus
Argus analyst Jasper Hellweg downgraded Bioverativ (BIVV) to Hold from Buy after the company announced a deal to be acquired by Sanofi (SNY) for $105 per share in cash. Hellweg says the strong run-up in the stock and the forthcoming acquisition have fully valued the stock at current levels.
AGN Allergan
$166.63

7.91 (4.98%)

01/29/18
01/29/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Allergan (AGN) upgraded to Overweight from Equal Weight at Barclays with analyst Douglas Tsao saying Allergan's aesthetics franchise is undervalued at current share levels. 2. Halliburton (HAL) upgraded to Neutral from Underweight at Atlantic Equities. 3. Ruth's Hospitality (RUTH) upgraded to Outperform from Market Perform at Raymond James with analyst Brian Vaccaro saying he is optimistic the high end steakhouse category can sustain into 2018 as strong business sentiment and corporate tax cuts bode well for T&E budgets. 4. Unilever (UN, UL) upgraded to Buy from Hold at Investec. 5. Kinder Morgan (KMI) upgraded to Buy from Hold at Argus with analyst Bill Selesky citing the company's "strong recent operational performance," the management's plan for a dividend hike, and attractive valuation in his rating change. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/25/18
BTIG
01/25/18
NO CHANGE
Target $7
BTIG
Buy
Synergy funding worries may be overdone, says BTIG
BTIG analyst Timothy Chiang noted that Synergy Pharmaceuticals (SGYP) announced that Trulance received expanded FDA approval for IBS-C, which puts it more on par with market leader Linzess from Ironwood (IRWD) and Allergan (AGN). He sees Trulance benefiting from increased payor access and believes the company will have sufficient cash in order to gain access to a second loan tranche of $100M expected by next month, stating that funding worries may be overdone. Chiang keeps a Buy rating and $7 price target on Synergy shares.
01/29/18
LEHM
01/29/18
UPGRADE
Target $230
LEHM
Overweight
Allergan upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Allergan to Overweight and raised his price target for the shares to $230 from $220. The Botox maker closed Friday down 19c to $186.93. Allergan's aesthetics franchise is undervalued at current share levels, Tsao tells investors in a research note. The analyst notes he's been on the sidelines with respect to the stock for three-plus years. Tsao says his firm's survey of 61 plastic surgeons and dermatologists validates Botox's market leader position. Physicians in the survey reported that 67% of Botox patients are "very satisfied" with results, which was well ahead of Dysport and Xeomin at 36% & 20%, respectively, Tsao writes.
AMRN Amarin
$3.63

0.1 (2.83%)

01/05/18
CANT
01/05/18
NO CHANGE
Target $10
CANT
Overweight
Cantor sees Amarin as top performing stock in 2018
Cantor Fitzgerald analyst Louise Chen says Amarin's preliminary 2017 results and 2018 outlook underscore her view that the company will be one of the top performing stocks in her coverage universe this year. Revenue growth is being driven by increased prescriptions for Vascepa capsules, Chen tells investors in a research note titled "AMRN Remains One of Our Top Catches of The Year." She believes the REDUCE-IT study results in 2018 will be positive and keeps an Overweight rating on the shares with a $10 price target.
12/20/17
CANT
12/20/17
NO CHANGE
Target $10
CANT
Overweight
Cantor more confident in $10 target for Amarin after management meetings
Cantor Fitzgerald analyst Louise Chen says that after spending two days with management, she has increased confidence in her Overweight rating and $10 price target for Amarin shares. The analyst believes the company's Vascepa can help lower deaths and the cost of care for patients with high triglycerides levels without increasing LDL-C. Chen believes this is still underappreciated in Amarin shares.
12/14/17
CANT
12/14/17
NO CHANGE
Target $10
CANT
Overweight
Cantor sees Vascepa benefits driving Amarin shares higher
Research recently presented to the American Heart Association by a key opinion leader showed over-the-counter fish oil supplements may contain mercury, are high in saturated fats and sugar, and may even raise lipid levels and deplete antioxidants, Cantor Fitzgerald analyst Louise Chen wrote yesterday in a research note titled "Something Smelly about Unregulated Fish Oil Contaminants." FDA approved products, such as Amarin's Vascepa, were found to be pure and safe, Chen adds. The research reinforced her view that the "differentiation and scientific benefit" of Vascepa will drive shares of Amarin higher. The analyst kept an Overweight rating on Amarin shares with a $10 price target.
01/23/18
CANT
01/23/18
NO CHANGE
Target $10
CANT
Overweight
Amarin shares have room to run ahead of data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen views this morning's announcement from Amarin as good news since the company is on track to report top-line results from the study before the end of Q3. Amarin this morning announced that its Reduce-It cardiovascular outcomes study has reported and documented more than 90% of the targeted 1,612 primary major adverse cardiovascular events. The analyst believes the shares have to room to run ahead of the data release. She keeps an Overweight rating on the name with a $10 price target.
MNTA Momenta
$16.25

0.25 (1.56%)

10/04/17
STFL
10/04/17
DOWNGRADE
STFL
Hold
Momenta downgraded to Hold from Buy at Stifel
10/04/17
10/04/17
DOWNGRADE
Target $15

Hold
Momenta downgraded after Mylan generic Copaxone approval at Stifel
As previously reported, Stifel analyst Thomas Shrader downgraded Momenta (MNTA) to Hold from Buy, saying that Mylan (MYL) receiving FDA approval of its 40 mg/mL and 20 mg/mL generic Copaxone variants is a "clear negative" for Momenta's Glatopa franchise. Based on that news, he has cut his forecast for Glatopa revenue and lowered his price target on Momenta shares to $15 from $22.
10/05/17
GSCO
10/05/17
NO CHANGE
Target $14
GSCO
Neutral
Momenta price target cut to $14 following Mylan gCopaxone approval at Goldman
Goldman analyst Dana Flanders lowered Momenta (MNTA) estimates and cut its price target on share to $14 from $18 following Mylan's (MYL) generic Copaxone approval. The analyst maintained a Neutral rating on Momenta given uncertainties on how the gCopaxone market will play out and lack of near-term pipeline catalysts.
02/13/18
WELS
02/13/18
NO CHANGE
WELS
Teva generic comes earlier than expected, says Wells Fargo
Wells Fargo analyst David Maris says Momenta Pharmaceuticals' (MNTA) generic approval of Teva Pharmaceutical's (TEVA) Copaxone came earlier than expected. As recently as the Q4 conference call on February 8, Teva management expected that another generic Copaxone approval would not come until April 2018, Maris tells investors in a research note. The analyst's forecasts assume a continued erosion of Copaxone sales, with sales of $700M in Q1, $500M sales in Q2 and $400M in Q3 and Q4. Maris keeps an Underperform rating on Teva.
RGNX Regenxbio
$26.80

0.2 (0.75%)

11/22/17
11/22/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Nutanix (NTNX) initiated with a Buy at Needham. 2. Regenxbio (RGNX) and Sangamo (SGMO) were initiated with an Overweight at Barclays. 3. Amedisys (AMED), HealthSouth (HLS), LHC Group (LHCG), and LifePoint (LPNT) were initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/05/18
RAJA
01/05/18
NO CHANGE
Target $39
RAJA
Outperform
Regenxbio weakness a buying opportunity, says Raymond James
11/22/17
LEHM
11/22/17
INITIATION
Target $38
LEHM
Overweight
Regenxbio initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Regenxbio with an Overweight rating and $38 price target. The analyst views the company's patent portfolio as "strong" and sees "significant upside" from its wholly owned RGX-314 program in wet age-related macular degeneration.
02/12/18
MZHO
02/12/18
INITIATION
MZHO
Neutral
Regenxbio initiated with a Neutral at Mizuho
Mizuho analyst Difei Yang started Regenxbio with a Neutral rating and $28 price target.

TODAY'S FREE FLY STORIES

03:30
12/14/18
12/14
03:30
12/14/18
03:30
General news
FX Action: USD-CAD has remained buoyant »

FX Action: USD-CAD has…

03:00
12/14/18
12/14
03:00
12/14/18
03:00
General news
FX Update: The Dollar and Yen has traded firmer »

FX Update: The Dollar…

01:55
12/14/18
12/14
01:55
12/14/18
01:55
General news
Asian Market Wrap: »

Asian Market Wrap:…

LVMHY

Lvmh ADR

$0.00

(0.00%)

, BEL

Belmond

$17.67

-0.3 (-1.67%)

19:07
12/13/18
12/13
19:07
12/13/18
19:07
Periodicals
LVMH near deal to acquire Belmond for $25 per share in cash, WSJ says »

LVMH (LVMHY) is near a…

LVMHY

Lvmh ADR

$0.00

(0.00%)

BEL

Belmond

$17.67

-0.3 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$175.87

-0.88 (-0.50%)

, JPM

JPMorgan

$101.08

0.03 (0.03%)

19:03
12/13/18
12/13
19:03
12/13/18
19:03
Periodicals
Goldman, JPMorgan, Citi invest in startup AccessFintech, Reuters says »

Goldman Sachs (GS),…

GS

Goldman Sachs

$175.87

-0.88 (-0.50%)

JPM

JPMorgan

$101.08

0.03 (0.03%)

C

Citi

$55.77

-0.22 (-0.39%)

CS

Credit Suisse

$11.26

-0.07 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

  • 26

    Feb

  • 15

    Apr

  • 13

    Jul

TIK

Tel-Instrument

$3.05

(0.00%)

, SGMS

Scientific Games

$15.77

-1.31 (-7.67%)

18:45
12/13/18
12/13
18:45
12/13/18
18:45
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: Tel-Instrument…

TIK

Tel-Instrument

$3.05

(0.00%)

SGMS

Scientific Games

$15.77

-1.31 (-7.67%)

XPO

XPO Logistics

$44.33

-15.92 (-26.42%)

COST

Costco

$226.41

-1.41 (-0.62%)

ADBE

Adobe

$247.71

2.27 (0.92%)

YECO

Yulong Eco-Materials

$5.00

0.42 (9.17%)

SBUX

Starbucks

$66.90

0.8 (1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

  • 13

    Dec

  • 14

    Dec

NXST

Nexstar

$85.78

-1.98 (-2.26%)

, SBGI

Sinclair Broadcast

$28.74

-1.2 (-4.01%)

18:31
12/13/18
12/13
18:31
12/13/18
18:31
Hot Stocks
DOJ reaches settlement with Nexstar »

The Department of Justice…

NXST

Nexstar

$85.78

-1.98 (-2.26%)

SBGI

Sinclair Broadcast

$28.74

-1.2 (-4.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBM

Hudbay Minerals

$4.79

-0.11 (-2.24%)

18:18
12/13/18
12/13
18:18
12/13/18
18:18
Hot Stocks
Hudbay Minerals says Waterton has withdrawn its special meeting requisition »

Hudbay Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FB

Facebook

$145.07

0.81 (0.56%)

, T

AT&T

$29.91

-0.26 (-0.86%)

18:17
12/13/18
12/13
18:17
12/13/18
18:17
Periodicals
Facebook seeks to sell cable TV subscriptions, Recode says »

Facebook (FB) is seeking…

FB

Facebook

$145.07

0.81 (0.56%)

T

AT&T

$29.91

-0.26 (-0.86%)

CBS

CBS

$47.90

-0.76 (-1.56%)

LGF.A

Lionsgate

$15.75

-0.87 (-5.23%)

LGF.B

Lionsgate

$14.60

-0.635 (-4.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

  • 30

    Jan

  • 20

    Mar

QCOM

Qualcomm

$58.09

0.36 (0.62%)

, AAPL

Apple

$170.93

1.84 (1.09%)

18:12
12/13/18
12/13
18:12
12/13/18
18:12
Periodicals
Judge says evidence of Apple switch can't be used in Qualcomm case, Reuters says »

A federal judge…

QCOM

Qualcomm

$58.09

0.36 (0.62%)

AAPL

Apple

$170.93

1.84 (1.09%)

INTC

Intel

$48.29

0.46 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

XPO

XPO Logistics

$44.33

-15.92 (-26.42%)

18:10
12/13/18
12/13
18:10
12/13/18
18:10
Hot Stocks
XPO Logistics says report from short selling firm 'intentionally misleading' »

XPO Logistics issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQNR

Equinor

$22.97

0.08 (0.35%)

18:08
12/13/18
12/13
18:08
12/13/18
18:08
Downgrade
Equinor rating change at Goldman Sachs »

Equinor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQNR

Equinor

$22.97

0.08 (0.35%)

18:03
12/13/18
12/13
18:03
12/13/18
18:03
Downgrade
Equinor rating change at Goldman Sachs »

Equinor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$170.93

1.84 (1.09%)

18:01
12/13/18
12/13
18:01
12/13/18
18:01
Periodicals
Apple Connect to shut down in 2019, Apple Insider says »

According to a report out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOB

Live Oak Bancshares

$15.19

0.09 (0.60%)

17:58
12/13/18
12/13
17:58
12/13/18
17:58
Hot Stocks
Live Oak Bancshares President Neil Lawrence Underwood buys 15,546 shares »

Live Oak Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.90

0.8 (1.21%)

17:55
12/13/18
12/13
17:55
12/13/18
17:55
Hot Stocks
Starbucks slips after cutting long-term EPS target »

Shares of Starbucks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

AAPL

Apple

$170.93

1.84 (1.09%)

17:53
12/13/18
12/13
17:53
12/13/18
17:53
Periodicals
Apple Connect to shut down in 2019 »

According to a report out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HESM

Hess Midstream Partners

$19.93

0.5 (2.57%)

17:53
12/13/18
12/13
17:53
12/13/18
17:53
Recommendations
Hess Midstream Partners analyst commentary at MUFG »

Hess Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$247.71

2.27 (0.92%)

17:46
12/13/18
12/13
17:46
12/13/18
17:46
Hot Stocks
Adobe says adding Marketo immediately adds revenue growth »

Says entire document…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

AES

AES Corp.

$15.78

-0.11 (-0.69%)

17:45
12/13/18
12/13
17:45
12/13/18
17:45
Conference/Events
AES Corp. management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MTN

Vail Resorts

$221.16

-3.77 (-1.68%)

17:42
12/13/18
12/13
17:42
12/13/18
17:42
Hot Stocks
Vail Resorts director John Sorte sells over $500,000 in company shares »

Vail Resorts director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YECO

Yulong Eco-Materials

$5.00

0.42 (9.17%)

17:42
12/13/18
12/13
17:42
12/13/18
17:42
Hot Stocks
Yulong Eco-Materials delisting from Nasdaq »

Yulong Eco-Materials has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OLP

One Liberty Properties

$26.17

-0.09 (-0.34%)

17:42
12/13/18
12/13
17:42
12/13/18
17:42
Hot Stocks
One Liberty Properties acquires industrial property in Missouri for $10M »

One Liberty Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNFI

United Natural Foods

$11.58

-1.18 (-9.25%)

17:38
12/13/18
12/13
17:38
12/13/18
17:38
Hot Stocks
United Natural Foods Chairman Steven Spinner buys 18,000 shares »

United Natural Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EME

Emcor

$64.78

-1.07 (-1.62%)

17:37
12/13/18
12/13
17:37
12/13/18
17:37
Initiation
Emcor initiated at Maxim »

Emcor initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.